Quantcast

Latest Naloxone Stories

2011-05-02 08:00:00

JERSEY CITY, N.J., May 2, 2011 /PRNewswire/ -- Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has been granted a patent by the State Intellectual Property Office of The People's Republic of China for naloxone sublingual film. The Chinese patent,...

2011-04-04 07:10:00

WARREN, N.J., April 4, 2011 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,897,080 from the United States Patent and Trademark Office (USPTO). The patent provides intellectual property protection for the Company's methods of pharmaceutical film preparation along with the incorporation of specific drugs and...

2011-03-25 14:11:00

SAN CARLOS, Calif., March 25, 2011 /PRNewswire/ -- PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, announced that Lynn R. Webster, M.D., FACPM, FASAM, Co-Founder and Medical Director of Lifetree Clinical Research, will introduce the Company's novel technology during the 27th Annual American Academy of Pain Medicine (AAPM) Meeting. Dr. Webster's presentation, titled "New Opioid Formulations and Delivery Systems,"...

2011-03-21 06:00:00

RALEIGH, N.C., March 21, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the issuance of a patent extending the exclusivity of the BioErodible MucoAdhesive (BEMA) drug delivery technology in Canada from 2017 to 2027. The patent was been reviewed by the Office of Patented Medicines for listing in the Canadian Patent Register and was found eligible for listing. (Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) BEMA is BDSI's core drug...

2011-03-15 11:06:00

SAN FRANCISCO, March 15, 2011 /PRNewswire/ -- AstraZeneca today announced enrolment of the first patient in the Phase III clinical programme for NKTR-118, an oral peripherally-acting opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC). The Phase III clinical programme is designed to investigate the safety and efficacy of NKTR-118 as a medicine to relieve opioid induced constipation, a common side effect of prescription opioids when used for chronic...

2011-03-14 20:52:24

Researchers from Boston University School of Medicine (BUSM) have found that for the majority of patients with opioid addiction, collaborative care with nurse care managers is a successful method of service delivery while effectively utilizing the time of physicians prescribing buprenorphine. The findings, which appear in the March 14 issue of the Archives of Internal Medicine, serve as a model of service delivery for facilitating access and improving outcomes in patients with opioid...

2011-03-11 05:30:00

RALEIGH, N.C., March 11, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announces that it has received definitive commitments from institutional investors for a private placement financing yielding gross proceeds of $15 million to BDSI. The financing is expected to close today. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Under the terms of a securities purchase agreement entered into with the investors, BDSI will sell an aggregate of...

2011-03-02 07:00:00

RALEIGH, N.C., March 2, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the positive outcome of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on the development program for BEMA Buprenorphine/Naloxone, BDSI's potential treatment for opioid dependence. The development program discussed is based on pharmacokinetic and safety data for a 505(b)(2) New Drug Application (NDA). (Logo:...

2011-02-22 09:36:00

WARREN, N.J., Feb. 22, 2011 /PRNewswire/ -- MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm® drug delivery technology, today announced that Reckitt Benckiser Pharmaceuticals Inc., a wholly-owned subsidiary of Reckitt Benckiser Group plc ("the Group") (LSE: RB), provided an update on U.S. market adoption of Suboxone® (buprenorphine HCl/naloxone HCl dihydrate) sublingual film for the treatment of opioid dependence during its announcement of...

2010-10-12 18:57:12

Helping to address the issue of medication adherence, persons with opioid dependence who had the medication buprenorphine implanted had less opioid use over 16 weeks, according to a study in the October 13 issue of JAMA. Dependence on opioids, in the form of heroin or prescription pain medications, is a significant health concern. A treatment that has been increasing in usage is the medication buprenorphine, with numerous studies supporting the efficacy of sublingually (beneath the tongue)...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related